LONG MINI-FUTURE - ELI LILLY & CO | Delayed Deutsche Boerse AG 10:40:21 2024-06-20 am EDT | ||
| 49.54 EUR | +1.52% |
|
| Current month | +18.13% | ||
| 1 month | +30.41% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 24-06-20 | 49.54 | +1.52% |
| 24-06-19 | 48.8 | +1.10% |
| 24-06-18 | 48.27 | -0.76% |
| 24-06-17 | 48.64 | +1.67% |
| 24-06-14 | 47.84 | +0.95% |
Delayed Quote Deutsche Boerse AG
Last update June 20, 2024 at 10:40 am EDT
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
Vontobel
|
| WKN | VU6E8X |
| ISIN | DE000VU6E8X3 |
| Date issued | 2023-04-18 |
| Strike | 368.1 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 3.59 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 49.54 € |
|---|---|
| Lowest since issue | 3.03 € |
| Spread | 0.03 € |
| Spread % | 0.06% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
891.5
USD
Average target price
855.4
USD
Spread / Average Target
-4.05%
- Stock Market
- Certificates
- Certificat
